Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
NCT03798106Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Apr 2019
- Primary completion
- Aug 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in soft tissue sarcoma (STS), sponsored by Yonsei University. Primary endpoint: Objective Response Rate at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03798106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798106.